BioPharma Credit Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	129.89	122.18	108.45	182.31	84.96
Loss (Gain) From Sale of Investments	-17.52	0.09	23.95	-5.95	23.75
Other Operating Activities	-0.04	0	0.01	0.03	0.02
Change in Accounts Receivable	-21.8	-11.48	-0.48	-9.83	-9.8
Change in Accounts Payable	0.56	1.12	-8.74	17.71	-2.49
Operating Cash Flow	91.1	111.91	123.18	184.28	96.44
Operating Cash Flow Growth	-18.60%	-9.15%	-33.15%	91.09%	66.06%
Investment in Securities	77.48	39.07	-1.66	48.19	-94.82
Investing Cash Flow	77.48	39.07	-1.66	48.19	-94.82
Repurchase of Common Stock	-51.27	-105.75	-17.22	-50.09	-
Common Dividends Paid	-79.96	-109.02	-68.95	-95.74	-96.17
Financing Cash Flow	-161.65	-280.42	-106.99	-206.62	-100.16
Foreign Exchange Rate Adjustments	0.04	-0	-0.01	-0.03	-0.02
Net Cash Flow	6.97	-129.43	14.53	25.82	-98.56
Levered Free Cash Flow	59.03	66.9	56.88	124.09	40.26
Unlevered Free Cash Flow	59.03	66.9	56.88	124.09	40.26
Change in Working Capital	-21.24	-10.36	-9.22	7.88	-12.29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.